Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.4% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 1 completed trials have results

Key Signals

3 recruiting

Enrollment reporting

Analytics

Phase 1/2

3(75.0%)

Phase 2

1(25.0%)

4Total

Phase 1/2(3)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials

NCT07899840Recruiting

Establishment of a Novel Flow Cytometric Diagnostic Assay to Effectively Evaluate Immune Reconstitution After Hematopoietic Stem Cell Transplantation for Acute Lymphoblastic Leukemia

Role: lead

NCT07877610Phase 1/2Recruiting

CARCIK CD123/33 for Refractory/Relapsed AML and BPDCN in Children and Adults

Role: lead

NCT05869279Phase 1/2Recruiting

Allogeneic CARCIK-CD19 in Adults/Pediatric B-cell NHL or Chronic Lymphocytic Leukemia

Role: lead

NCT03389035Phase 1/2Completed

Transposon-manipulated Allogeneic CARCIK-CD19 Cells in Pediatric and Adult Patients With r/r ALL Post HSCT

Role: lead

NCT05252403Phase 2Unknown

Residual Disease Driven Strategy for CARCIK (CD19) in Adults/Pediatric BCP-ALL

Role: lead

All 5 trials loaded